Tempus AI Shares Slide 12% as Q4 Results Disappoint

Investing

02-25

Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.

The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.

Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.

"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year," said Eric Lefkofsky, Founder and CEO of Tempus.

For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.

Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1161962625"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161962625\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1161962625?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161962625","market":"us","top_or_hot":-1,"title":"Tempus AI Shares Slide 12% as Q4 Results Disappoint","media":"Investing","content":"<html><head></head><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f15d2734141482e6aab6365f7e340444\" tg-height=\"392\" tg-width=\"415\"/></p><p style=\"text-align: start;\">The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.</p><p style=\"text-align: start;\">Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.</p><p style=\"text-align: start;\">\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.</p><p style=\"text-align: start;\">For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.</p><p style=\"text-align: start;\">Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.</p></body></html>","source":"hk_investing_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Tempus AI Shares Slide 12% as Q4 Results Disappoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Shares Slide 12% as Q4 Results Disappoint\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">Investing</strong><span class=\"h-time small\">2025-02-25 07:28</span>\n</p>\n</header>\n<article>\n<p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f15d2734141482e6aab6365f7e340444\" tg-height=\"392\" tg-width=\"415\"/></p><p style=\"text-align: start;\">The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.</p><p style=\"text-align: start;\">Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.</p><p style=\"text-align: start;\">\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.</p><p style=\"text-align: start;\">For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.</p><p style=\"text-align: start;\">Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.</p>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329\">Investing</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329","article_id":"1161962625","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161962625","pubTimestamp":1740439713,"columns":[],"sourceInfo":{"source_id":"hk_investing_stock","name":"Investing"},"weMediaInfo":null,"summary":"$Tempus AI$ reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 4","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"第四季度业绩令人失望，Tempus AI股价下跌12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.1},"content_text":"Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}